Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours (2001)

  • Authors:
  • USP affiliated authors: ZATZ, MAYANA - IB ; BUENO, MARIA RITA DOS SANTOS E PASSOS - IB
  • USP Schools: IB; IB
  • DOI: 10.1038/sj.ejhg.5200721
  • Subjects: SÍNDROME DE DOWN
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    DOI or search this record in
    Informações sobre o DOI: 10.1038/sj.ejhg.5200721 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo é de acesso aberto
    • URL de acesso aberto
    • Cor do Acesso Aberto: bronze
    Informações sobre o Citescore
  • Título: European Journal of Human Genetics

    ISSN: 1018-4813

    Citescore - 2017: 3.05

    SJR - 2017: 1.842

    SNIP - 2017: 1.096


  • How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      ZORICK, Todd S.; MUSTACCHI, Zan; BANDO, Sílvia Yumi; et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. European Journal of Human Genetics, Hants [England], v. 9, p. 811-814, 2001. DOI: 10.1038/sj.ejhg.5200721.
    • APA

      Zorick, T. S., Mustacchi, Z., Bando, S. Y., Zatz, M., Moreira-Filho, C. A., Olsen, B., & Passos-Bueno, M. R. (2001). High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. European Journal of Human Genetics, 9, 811-814. doi:10.1038/sj.ejhg.5200721
    • NLM

      Zorick TS, Mustacchi Z, Bando SY, Zatz M, Moreira-Filho CA, Olsen B, Passos-Bueno MR. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. European Journal of Human Genetics. 2001 ; 9 811-814.
    • Vancouver

      Zorick TS, Mustacchi Z, Bando SY, Zatz M, Moreira-Filho CA, Olsen B, Passos-Bueno MR. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. European Journal of Human Genetics. 2001 ; 9 811-814.

    Referências citadas na obra
    Epstein CJ . Down syndrome (trisomy 21) in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease. New York 1995 vol 1: pp 749–794
    Satgé D, Sommelet D, Geneix A, Nishi M, Malet P, Vekemans M . A tumor profile in Down Syndrome Am J Med Genet 1998 78: 207–216
    Hasle H, Clemmensen IH, Mikkelsen M . Risks of leukaemia and solid tumours in individuals with Down's syndrome Lancet 2000 355: 165–169
    Satgé D, Sasco AJ, Carlsen NLT et al. A lack of neuroblastoma in Down Syndrome: A study from 11 European countries Cancer Res 1998 58: 448–452
    Hattori M, Fujiyama A, Taylor TD et al. The DNA sequence of human chromosome 21. The chromosome 21 mapping and sequencing consortium Nature 2000 405: 311–319
    Sakata K, Tamura G, Nishizuka S et al. Commonly deleted regions on the long arm of chromosome 21 in differentiated adenocarcinoma of the stomach Genes Chromosomes Cancer 1997 18: 318–321
    Ohgaki K, Iida A, Kasumi F et al. Mapping of a new target region of allelic loss to a 6-cM interval at 21q21 in primary breast cancers Genes Chromosomes Cancer 1998 23: 244–247
    Schwendel A, Richard F, Langreck H et al. Chromosome alterations in breast carcinomas: frequent involvement of DNA losses including chromosomes 4q and 21q Br J Cancer 1998 78: 806–811
    O´Reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 1997 88: 277–285
    Muragaki Y, Timmons S, Griffith CM et al. Mouse Col18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones Proc Natl Acad Sci USA 1995 92: 8763–8767
    Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SL . Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases Proc Natl Acad Sci USA 2000 97: 4802–4807
    Feldman AL, Restifo NP, Alexander HR et al. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice Cancer Res 2000 60: 1503–1506
    Saarela J, Rehn M, Oikarinen A, Autio-Harmainen H, Pihlajaniemi T . The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans Am J Path 1998 253: 611–626
    Sertie AL, Sossi V, Camargo AA, Zatz M, Brahe C, Passos-Bueno MR . Collagen XVIII, containing an endogenous inhibitor of angiogenesis and tumor growth, plays a critical role in the maintenance of retinal structure and in neural tube closure (Knobloch syndrome) Hum Mol Genet 2000 9: 2051–2058
    Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W . Secreted cathepsin L generates endostatin from collagen XVIII EMBO J 2000 19: 1187–1194
    Sasaki T, Fukai N, Mann K, Gohring W, Olsen BR, Timpl R . Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin EMBO J 1998 17: 4249–4256
    Musso O, Rehn M, Theret N et al. Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas Cancer Res 2001 61: 45–49
    Feldman AL, Tamarkin L, Paciotti GF et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer Clin Cancer Res 2000 6: 4628–4634
    Hebbar M, Peyrat J-P, Hornez L, Hatron P-Y, Hachulla E, Devulder B . Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with Systemic Sclerosis Arth Rheum 2000 43: 889–893
    Shichiri M, Hirata Y . Antiangiogenesis signals by endostatin FASEB J 2001 15: 1044–1053
    Jiang L, Jha V, Dhanabal M, Sukhatme VP, Alper SL . Intracellular Ca2+ signaling in endothelial cells by the angiogenesis inhibitors endostatin and angiostatin AJP Cell Physiol 2001 280: C1140–C1150
    Karumanchi SA, Jha V, Ramchandran R et al. Cell surface glypicans are low-affinity endostatin receptors Mol Cell 2001 7: 811–822